Pneumococcal Vaccines Clinical Trial
Official title:
Parents' Enhanced Reminder Intervention to Improve Children's Timely Completion of Immunization Series of Pneumococcal Vaccine at the 12-month's Visit
The goal of this clinical trial is to assess the effectiveness of enhanced email reminders in improving vaccine coverage at the 12-month visit in CANImmunize app users. The main questions it aims to answer are: - Do enhanced email reminders improve coverage of the 12- month dose of the pneumococcal vaccine and the timely completion of its immunization series at the 12-month's visit in CANImmunize app users? - What are the predictors of predictors of timely completion of the 12-month's series of pneumococcal vaccines in the CANImmunize app users? Participants will be randomized to either receive enhanced reminder/recall materials via email or the standard CANImmunize notifications. Researchers will compare the enhanced reminder group to the standard notification group to see if there is a difference in vaccine coverage at the 12-month visit.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01953510 -
Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam
|
Phase 2/Phase 3 | |
Completed |
NCT05540028 -
Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
|
Phase 1 | |
Recruiting |
NCT05298800 -
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
|
Phase 4 | |
Active, not recruiting |
NCT06077656 -
Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
|
Phase 2 | |
Active, not recruiting |
NCT06151288 -
Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT00574548 -
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
|
Phase 3 | |
Not yet recruiting |
NCT06271681 -
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
|
Phase 4 | |
Active, not recruiting |
NCT05844423 -
Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants
|
Phase 2 | |
Completed |
NCT00824655 -
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children
|
Phase 3 | |
Completed |
NCT01646398 -
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
|
Phase 3 | |
Completed |
NCT00464945 -
Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
Completed |
NCT03893448 -
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
|
Phase 3 | |
Completed |
NCT05297578 -
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
|
Phase 2 | |
Completed |
NCT01964716 -
13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.
|
Phase 3 | |
Completed |
NCT05266456 -
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01537185 -
Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
|
Phase 1 | |
Recruiting |
NCT00999739 -
Conjugate And Polysaccharide Vaccines Compared With Polysaccharide Vaccine In Hiv-Infected Adults
|
Phase 3 | |
Not yet recruiting |
NCT05721456 -
Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.
|
Phase 3 | |
Active, not recruiting |
NCT02012309 -
Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses
|
N/A | |
Completed |
NCT01392378 -
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13®
|
Phase 4 |